Optime Care Announces Enhanced Partnership with Rigel Pharmaceuticals for GAVRETO® Patients

Press Releases

Optime Care Announces Enhanced Partnership with Rigel Pharmaceuticals for GAVRETO® Patients 


St. Louis, MO – June 27, 2024 – Optime Care, a nationally recognized specialty pharmacy and an AscellaHealth Company, today announces a contractual partnership with Rigel Pharmaceuticals, Inc, effective July 1, 2024, bringing its comprehensive suite of services to support patients using GAVRETO® (pralsetinib)GAVRETO® is a targeted therapy that is taken by mouth once daily and is used to treat certain cancers caused by abnormal RET genes. 


Optime Care’s offerings for life sciences manufacturers encompass pre-commercialization and market access expertise, exclusive distribution partnerships and national medication fulfillment. Seamless treatment is ensured through high-touch patient support and HUB services designed to enhance patient outcomes. 

“Our dedicated team at Optime Care is excited to expand our long-standing partnership with Rigel Pharmaceuticals and support GAVRETO® patients,” says Stephanie Wasilewski, PharmD, General Manager, Optime Care. “Our comprehensive suite of services and deep commitment to personalized care optimize therapeutic outcomes throughout the treatment journey,” says Stephanie Wasilewski, PharmD, General Manager, Optime Care. 

Optime Care specialists excel in communication, optimizing the patient journey through personalized clinical guidance and ongoing support for patients and their familiesProfessionals with deep understanding of complex, chronic disease have specialized experience that enhances patient access to essential therapiesstreamlines care coordination, assists with insurance coverage to address financial needs and identifies financial assistance programs. 

Rigel Pharmaceuticals, Inc. has an established relationship with Optime Care and based this selection for the management of GAVRETO® patients on the Company’s expertise with specialized, complex diseases and comprehensive suite of integrated patient management and HUB services. This includes distribution, patient intake, prescription fulfillment, prior authorization support, custom clinical programs, reimbursement services and financial assistance. 


"Optime Care has consistently demonstrated exceptional expertise and commitment to patient care, making them an ideal partner for managing GAVRETO® patients,” says Scott Yohe, VP of market accessRigel Pharmaceuticals. Their comprehensive services ensure that patients have access to the necessary resources and guidance, support that leads to improved therapeutic outcomes. We are excited to strengthen our collaboration and continue to make a positive impact on the lives of those affected by cancers caused by abnormal RET genes. 




Powered By GrowthZone